Free Trial

Rentokil Initial (RTOKY) Financials

Rentokil Initial logo
$23.85 +0.51 (+2.19%)
As of 05/23/2025
Annual Income Statements for Rentokil Initial

Annual Income Statements for Rentokil Initial

This table shows Rentokil Initial's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Income / (Loss) Attributable to Common Shareholders
384 486 280 355 254
Consolidated Net Income / (Loss)
384 486 280 355 254
Net Income / (Loss) Continuing Operations
384 486 280 355 254
Total Pre-Tax Income
507 628 357 439 314
Total Operating Income
687 796 383 468 402
Total Gross Profit
758 846 412 468 402
Total Revenue
6,806 6,849 4,485 3,992 3,828
Operating Revenue
6,806 6,849 4,485 3,992 3,828
Total Cost of Revenue
6,049 6,003 4,074 3,524 3,427
Operating Cost of Revenue
6,049 6,003 4,074 3,524 3,427
Total Operating Expenses
70 50 29 0.00 0.00
Impairment Charge
70 50 29 0.00 0.00
Total Other Income / (Expense), net
-180 -168 -25 -30 -87
Interest Expense
247 241 95 46 107
Interest & Investment Income
58 61 59 5.40 8.19
Other Income / (Expense), net
8.76 11 11 11 11
Income Tax Expense
123 143 77 84 60
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)
-56 287 356 -16 92
Basic Earnings per Share
$0.15 $0.19 $0.14 $0.14 $0.10
Weighted Average Basic Shares Outstanding
2.52B 2.52B 2.52B - -
Diluted Earnings per Share
$0.15 $0.19 $0.14 $0.14 $0.10
Weighted Average Diluted Shares Outstanding
2.52B 2.52B 2.52B - -
Weighted Average Basic & Diluted Shares Outstanding
2.52B 2.52B 2.52B - -

Quarterly Income Statements for Rentokil Initial

No quarterly income statements for Rentokil Initial are available.


Annual Cash Flow Statements for Rentokil Initial

This table details how cash moves in and out of Rentokil Initial's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Change in Cash & Equivalents
177 54 -827 -398 382
Net Cash From Operating Activities
392 362 402 437 478
Net Cash From Continuing Operating Activities
392 362 402 437 478
Net Income / (Loss) Continuing Operations
0.00 0.00 0.00 0.00 0.00
Depreciation Expense
353 349 307 278 -
Non-Cash Adjustments To Reconcile Net Income
39 13 95 123 478
Net Cash From Investing Activities
-215 -308 -1,229 -616 -434
Net Cash From Continuing Investing Activities
-215 -308 -1,229 -616 -434
Acquisitions
-215 -308 -1,229 -625 -265
Net Cash From Financing Activities
0.00 0.00 0.00 -225 462
Net Cash From Continuing Financing Activities
0.00 0.00 0.00 -225 462
Cash Interest Received
45 32 16 6.75 11

Quarterly Cash Flow Statements for Rentokil Initial

No quarterly cash flow statements for Rentokil Initial are available.


Annual Balance Sheets for Rentokil Initial

This table presents Rentokil Initial's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Total Assets
12,917 13,894 14,163 5,736
Total Current Assets
2,613 3,437 3,909 1,814
Cash & Equivalents
1,158 1,990 2,621 902
Short-Term Investments
2.50 19 1.21 5.40
Accounts Receivable
1,138 1,121 1,002 711
Inventories, net
287 264 242 184
Current Deferred & Refundable Income Taxes
28 42 43 12
Plant, Property, & Equipment, net
629 636 598 537
Plant, Property & Equipment, gross
629 636 598 537
Total Noncurrent Assets
9,675 9,821 9,656 3,384
Long-Term Investments
73 83 104 41
Intangible Assets
8,900 8,974 8,820 2,921
Noncurrent Deferred & Refundable Income Taxes
43 55 52 57
Other Noncurrent Operating Assets
660 710 680 366
Total Liabilities & Shareholders' Equity
13,215 14,179 14,422 5,837
Total Liabilities
7,921 8,970 9,473 4,131
Total Current Liabilities
3,224 3,286 3,429 1,877
Short-Term Debt
1,460 1,445 1,624 620
Accounts Payable
1,400 1,458 1,408 1,031
Current Deferred & Payable Income Tax Liabilities
54 61 72 82
Other Current Liabilities
311 322 324 143
Total Noncurrent Liabilities
4,697 5,683 6,045 2,255
Long-Term Debt
3,128 4,018 4,316 1,696
Capital Lease Obligations
394 405 393 188
Noncurrent Deferred & Payable Income Tax Liabilities
640 659 620 146
Noncurrent Employee Benefit Liabilities
31 36 36 36
Other Noncurrent Operating Liabilities
503 566 680 189
Total Equity & Noncontrolling Interests
5,294 5,209 4,949 1,706
Total Preferred & Common Equity
5,295 5,211 4,950 1,708
Preferred Stock
19 18 11 9.45
Total Common Equity
5,276 5,193 4,939 1,698
Common Stock
31 32 30 26
Retained Earnings
4,515 4,483 3,988 4,274
Other Equity Adjustments
730 678 921 -2,601
Noncontrolling Interest
-1.25 -1.27 -1.21 -1.35

Quarterly Balance Sheets for Rentokil Initial

No quarterly balance sheets for Rentokil Initial are available.


Annual Metrics And Ratios for Rentokil Initial

This table displays calculated financial ratios and metrics derived from Rentokil Initial's official financial filings.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Growth Metrics
- - - - -
Revenue Growth
-0.63% 52.70% 12.36% 4.28% 0.00%
EBITDA Growth
-9.32% 65.18% -7.51% 83.62% 0.00%
EBIT Growth
-13.83% 105.20% -17.85% 16.20% 0.00%
NOPAT Growth
-15.34% 105.12% -20.84% 16.75% 0.00%
Net Income Growth
-20.83% 73.28% -21.09% 39.77% 0.00%
EPS Growth
-20.83% 38.13% -1.42% 41.28% 0.00%
Operating Cash Flow Growth
8.29% -10.01% -8.06% -8.49% 0.00%
Free Cash Flow Firm Growth
123.75% 104.40% -73.90% 0.00% 0.00%
Invested Capital Growth
0.52% 4.85% 162.53% 0.00% 0.00%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics
- - - - -
Gross Margin
11.13% 12.35% 9.18% 11.73% 10.49%
EBITDA Margin
15.42% 16.89% 15.62% 18.97% 10.77%
Operating Margin
10.10% 11.63% 8.54% 11.73% 10.49%
EBIT Margin
10.23% 11.80% 8.78% 12.01% 10.77%
Profit (Net Income) Margin
5.65% 7.09% 6.25% 8.89% 6.64%
Tax Burden Percent
75.80% 77.28% 78.38% 80.92% 80.87%
Interest Burden Percent
72.84% 77.76% 90.80% 91.55% 76.16%
Effective Tax Rate
24.20% 22.72% 21.62% 19.08% 19.13%
Return on Invested Capital (ROIC)
5.97% 7.24% 5.24% 23.99% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
2.04% 3.44% 4.41% 20.68% 0.00%
Return on Net Nonoperating Assets (RNNOA)
1.35% 2.32% 3.18% 17.62% 0.00%
Return on Equity (ROE)
7.32% 9.56% 8.42% 41.61% 0.00%
Cash Return on Invested Capital (CROIC)
5.46% 2.50% -84.43% -176.01% 0.00%
Operating Return on Assets (OROA)
5.19% 5.76% 3.96% 8.35% 0.00%
Return on Assets (ROA)
2.87% 3.46% 2.82% 6.19% 0.00%
Return on Common Equity (ROCE)
7.30% 9.53% 8.40% 41.42% 0.00%
Return on Equity Simple (ROE_SIMPLE)
7.26% 9.32% 5.66% 20.79% 0.00%
Net Operating Profit after Tax (NOPAT)
521 616 300 379 325
NOPAT Margin
7.66% 8.99% 6.69% 9.50% 8.48%
Net Nonoperating Expense Percent (NNEP)
3.94% 3.80% 0.83% 3.31% 0.00%
Return On Investment Capital (ROIC_SIMPLE)
5.07% 5.56% 2.66% - -
Cost of Revenue to Revenue
88.87% 87.65% 90.82% 88.27% 89.51%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
1.03% 0.73% 0.65% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
696 808 394 479 412
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
1,049 1,157 700 757 412
Valuation Ratios
- - - - -
Price to Book Value (P/BV)
2.42 2.72 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.88 2.07 0.00 0.00 0.00
Price to Earnings (P/E)
33.23 29.13 0.00 0.00 0.00
Dividend Yield
2.28% 1.77% 0.00% 0.00% 0.00%
Earnings Yield
3.01% 3.43% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.89 2.06 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
2.43 2.62 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
15.76 15.50 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
23.76 22.20 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
31.74 29.14 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
42.21 49.56 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
34.75 84.31 0.00 0.00 0.00
Leverage & Solvency
- - - - -
Debt to Equity
0.94 1.13 1.28 1.47 0.00
Long-Term Debt to Equity
0.67 0.85 0.95 1.10 0.00
Financial Leverage
0.66 0.67 0.72 0.85 0.00
Leverage Ratio
2.55 2.76 2.99 3.36 0.00
Compound Leverage Factor
1.86 2.15 2.71 3.08 0.00
Debt to Total Capital
48.48% 52.97% 56.13% 59.46% 0.00%
Short-Term Debt to Total Capital
14.21% 13.05% 14.40% 14.72% 0.00%
Long-Term Debt to Total Capital
34.28% 39.93% 41.74% 44.74% 0.00%
Preferred Equity to Total Capital
0.18% 0.16% 0.10% 0.22% 0.00%
Noncontrolling Interests to Total Capital
-0.01% -0.01% -0.01% -0.03% 0.00%
Common Equity to Total Capital
51.35% 46.88% 43.78% 40.35% 0.00%
Debt to EBITDA
4.75 5.07 9.04 3.30 0.00
Net Debt to EBITDA
3.57 3.26 5.15 2.05 0.00
Long-Term Debt to EBITDA
3.36 3.82 6.72 2.49 0.00
Debt to NOPAT
9.56 9.53 21.11 6.60 0.00
Net Debt to NOPAT
7.19 6.13 12.02 4.10 0.00
Long-Term Debt to NOPAT
6.76 7.19 15.69 4.97 0.00
Altman Z-Score
2.11 2.10 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio
0.32% 0.26% 0.27% 0.47% 0.00%
Liquidity Ratios
- - - - -
Current Ratio
0.81 1.05 1.14 0.97 0.00
Quick Ratio
0.71 0.95 1.06 0.86 0.00
Cash Flow Metrics
- - - - -
Free Cash Flow to Firm (FCFF)
476 213 -4,836 -2,781 0.00
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 282.26%
Free Cash Flow to Firm to Interest Expense
1.93 0.88 -50.69 -60.59 0.00
Operating Cash Flow to Interest Expense
1.59 1.50 4.22 9.53 4.49
Operating Cash Flow Less CapEx to Interest Expense
1.59 1.50 4.22 9.74 2.90
Efficiency Ratios
- - - - -
Asset Turnover
0.51 0.49 0.45 0.70 0.00
Accounts Receivable Turnover
6.02 6.45 5.23 5.61 0.00
Inventory Turnover
21.98 23.76 19.16 19.19 0.00
Fixed Asset Turnover
10.77 11.10 7.90 7.43 0.00
Accounts Payable Turnover
4.23 4.19 3.34 3.42 0.00
Days Sales Outstanding (DSO)
60.59 56.59 69.73 65.05 0.00
Days Inventory Outstanding (DIO)
16.61 15.36 19.05 19.02 0.00
Days Payable Outstanding (DPO)
86.22 87.13 109.30 106.84 0.00
Cash Conversion Cycle (CCC)
-9.02 -15.18 -20.52 -22.77 0.00
Capital & Investment Metrics
- - - - -
Invested Capital
8,745 8,700 8,297 3,160 0.00
Invested Capital Turnover
0.78 0.81 0.78 2.53 0.00
Increase / (Decrease) in Invested Capital
45 403 5,137 3,160 0.00
Enterprise Value (EV)
16,540 17,937 0.00 0.00 0.00
Market Capitalization
12,774 14,144 0.00 0.00 0.00
Book Value per Share
$2.09 $2.06 $1.96 $0.00 $0.00
Tangible Book Value per Share
($1.44) ($1.50) ($1.54) $0.00 $0.00
Total Capital
10,276 11,077 11,282 4,209 0.00
Total Debt
4,982 5,868 6,333 2,503 0.00
Total Long-Term Debt
3,522 4,423 4,709 1,883 0.00
Net Debt
3,749 3,776 3,607 1,555 0.00
Capital Expenditures (CapEx)
0.00 0.00 0.00 -9.45 169
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-312 -414 -517 -350 0.00
Debt-free Net Working Capital (DFNWC)
849 1,595 2,105 558 0.00
Net Working Capital (NWC)
-611 150 481 -62 0.00
Net Nonoperating Expense (NNE)
137 130 20 24 71
Net Nonoperating Obligations (NNO)
3,451 3,490 3,348 1,454 0.00
Total Depreciation and Amortization (D&A)
353 349 307 278 0.00
Debt-free, Cash-free Net Working Capital to Revenue
-4.58% -6.05% -11.52% -8.76% 0.00%
Debt-free Net Working Capital to Revenue
12.47% 23.29% 46.93% 13.97% 0.00%
Net Working Capital to Revenue
-8.98% 2.20% 10.72% -1.56% 0.00%
Earnings Adjustments
- - - - -
Adjusted Basic Earnings per Share
$0.15 $0.15 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding
2.52B 2.52B 0.00 0.00 0.00
Adjusted Diluted Earnings per Share
$0.15 $0.15 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
2.52B 2.52B 0.00 0.00 0.00
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.52B 2.52B 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
574 654 323 379 325
Normalized NOPAT Margin
8.44% 9.55% 7.20% 9.50% 8.48%
Pre Tax Income Margin
7.45% 9.17% 7.97% 10.99% 8.21%
Debt Service Ratios
- - - - -
EBIT to Interest Expense
2.82 3.35 4.13 10.44 3.87
NOPAT to Interest Expense
2.11 2.56 3.15 8.26 3.05
EBIT Less CapEx to Interest Expense
2.82 3.35 4.13 10.65 2.28
NOPAT Less CapEx to Interest Expense
2.11 2.56 3.15 8.46 1.46
Payout Ratios
- - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Rentokil Initial

No quarterly metrics and ratios for Rentokil Initial are available.


Frequently Asked Questions About Rentokil Initial's Financials

When does Rentokil Initial's fiscal year end?

According to the most recent income statement we have on file, Rentokil Initial's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Rentokil Initial's net income changed over the last 4 years?

Rentokil Initial's net income appears to be on an upward trend, with a most recent value of $384.39 million in 2024, rising from $254.02 million in 2020. The previous period was $485.51 million in 2023.

What is Rentokil Initial's operating income?
Rentokil Initial's total operating income in 2024 was $687.40 million, based on the following breakdown:
  • Total Gross Profit: $757.52 million
  • Total Operating Expenses: $70.12 million
How has Rentokil Initial revenue changed over the last 4 years?

Over the last 4 years, Rentokil Initial's total revenue changed from $3.83 billion in 2020 to $6.81 billion in 2024, a change of 77.8%.

How much debt does Rentokil Initial have?

Rentokil Initial's total liabilities were at $7.92 billion at the end of 2024, a 11.7% decrease from 2023, and a 91.7% increase since 2021.

How much cash does Rentokil Initial have?

In the past 3 years, Rentokil Initial's cash and equivalents has ranged from $901.80 million in 2021 to $2.62 billion in 2022, and is currently $1.16 billion as of their latest financial filing in 2024.

How has Rentokil Initial's book value per share changed over the last 4 years?

Over the last 4 years, Rentokil Initial's book value per share changed from 0.00 in 2020 to 2.09 in 2024, a change of 209.2%.



This page (OTCMKTS:RTOKY) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners